secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001193125-26-107276
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics FY2025 net loss $21.2M; cash $46.8M, ALS trial enrolling
--------------------------------------------------------------------------

- Cash and cash equivalents $46.8M at Dec 31, 2025; collaboration revenue $7.9M (up from $3.6M).
- R&D expenses $16.7M (up $4.8M); net loss $21.2M vs $14.9M in FY2024.
- COYA 302 ALSTARS Phase 2 trial actively enrolling across ~25 sites in US and Canada.
- FDA accepted IND for COYA 302 in frontotemporal dementia (FTD); Phase 2a expected 2H2026.
- Completed $23M public offering and $11.1M private placement; cash runway into 2H2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000119312526107276/0001193125-26-107276-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000119312526107276/coya-20260316.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-107276

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer